Griffithsin-based Rectal Microbicide for PREvention of Viral ENTry (PREVENT)
Status:
Terminated
Trial end date:
2021-02-04
Target enrollment:
Participant gender:
Summary
This is the first-in-human clinical study to see if a single dose of an investigational enema
made from a modified plant protein called Q-Griffithsin is safe, tolerated, and acceptable
for use by healthy adults 18-45 years of age who practice receptive anal intercourse.
Phase:
Phase 1
Details
Lead Sponsor:
Rhonda Brand
Collaborators:
Intrucept Biomedicine LLC National Institute of Allergy and Infectious Diseases (NIAID)